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Background: Class I antiarrhythmic drugs can promote the organization of atrial ﬁbrillation
(AF) and sometimes converts AF into atrial ﬂutter (AFL) concomitant with diﬃculty of rate
control. We studied the usefulness of Bepridil, which exhibits a class III-like eﬀect, for class I
drug-induced AFL in patients with paroxysmal AF.
Methods: The study population consisted of 17 consecutive patients (15 men, mean age
65 8 years) with AFL converted from paroxysmal AF following oral treatment of class IA
or IC antiarrhythmic agents including pilsicainide (n ¼ 8), cibenzoline (n ¼ 5), ﬂecainide
(n ¼ 2), aprindine (n ¼ 1), and propafenone with cibenzoline (n ¼ 1). After the occurrence of
AFL, class I drug was replaced by bepridil with a dose of 100–200mg per day in all patients.
Results: After the treatment with bepridil, 15 (88%) out of the 17 patients restored sinus
rhythm after 1 to 68 days (average of 21 days). In 12 (80%) of the 15 patients, sinus rhythm
was maintained for an average of 23.6 months (range of 1 to 62 months) follow-up period.
Although torsade de pointes was not recognized, a marked QT prolongation (0.60 sec) was
observed in one patient during the administration of bepridil at a daily dose of 200mg. In this
patient, QT interval was normalized (0.45 sec) after reduction of bepridil to 150mg daily.
Conclusion: Bepridil treatment may be safe and eﬀective for class I drug-induced AFL in
patients with paroxysmal AF to restore and maintain sinus rhythm as an alternative therapy
for catheter ablation. However, the QT interval must be carefully monitored during this
medication.
(J Arrhythmia 2008; 24: 71–75)
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Introduction
Class IA or IC antiarrhythmic agents are frequent-
ly used as a ﬁrst-line therapy in the management of
patients with atrial ﬁbrillation (AF). However, these
agents may result in the induction of atrial ﬂutter
(AFL), especially if class IC drugs are used (so-
called IC ﬂutter).1) The incidence of class I drug-
induced AFL in the treatment of AF has been
reported as 3.5 to 24%.2–4) Although catheter
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ablation for class I drug-related AFL in patients with
AF has been established as a hybrid therapy,
continuous medication is needed for prevention of
AF in most of the patients.3,5–7) In addition, not all
patients are good candidates for catheter ablation and
they may not agree to undergo the therapy, espe-
cially if they are elderly. Bepridil, which has a class
III-like eﬀect, has been reported to be eﬀective for
the treatment of AF8,9) and AFL.10) Therefore, we
studied the clinical eﬃcacy of Bepridil for AFL after
treatment with class I antiarrhythmic agents in
patients with paroxysmal AF.
Methods
The study population consisted of 17 consecutive
patients (15 men, mean age of 65 8 years; range,
49 to 76 years) with ‘‘common type’’ AFL converted
following oral treatment with class I antiarrhythmic
agents for paroxysmal AF. Common type AFL was
deﬁned as a predominantly negative, sawtooth-like
atrial activation pattern in the inferior leads, with
positive atrial deﬂections in lead V1 and negative
deﬂections in lead V6. The history of paroxysmal AF
ranged from 1 to 144 months (average, 45.2 months).
Eleven patients had underlying cardiovascular dis-
ease: 7 patients suﬀered from hypertension, 2 from
post-myocardial infarction, one from aortic stenosis,
and another from mitral stenosis. All patients had
their left ventricular function evaluated using echo-
cardiography before the bepridil administration. The
mean left ventricular ejection fraction was 68 8%
and left atrial diameter (LAD) was 40:3 6:1mm.
The antiarrhythmic agents causing AFL were pilsi-
cainide (n ¼ 8), cibenzoline (n ¼ 5), ﬂecainide
(n ¼ 2), aprindine (n ¼ 1), and propafenon with
cibenzoline (n ¼ 1). After the occurrence of AFL,
class I drugs were discontinued in all patients and
bepridil was started with a dose of 100–150mg per
day. If sinus rhythm was not restored and QT
interval was not prolonged more than 0.50 sec, the
bepridil dose was increased to 150–200mg daily
after one or 2 weeks. If sinus rhythm was restored,
the treatment was maintained unless adverse com-
plications occurred. For rate control, digoxin, beta-
blocker, and calcium antagonists such as verapamil
or diltiazem were used concomitantly if required. In
all patients, anticoagulation therapy with warfarin
was concurrently started to prevent thromboembolic
complications.
Statistical analysis
Continuous variables are presented as the mean
SD and were compared by paired t test. Categorical
variables were compared by Fisher’s exact test. A p
value <0:05 was considered statistically signiﬁcant.
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Figure 1 Time duration to restore sinus rhythm after bepridil treatment in each patient.
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Results
After treatment with bepridil, 15 (88%) out of 17
patients restored sinus rhythm after 1 to 68 days
(average of 21 days) (Figure 1). Although paroxys-
mal AF occurred in 3 patients, sinus rhythm was
maintained in 12 (80%) of 15 patients for an average
of 23.6 months (range of 1 to 62 months) follow-up
period. The maintenance dose of bepridil was
100mg/day in 1 patient, 150mg/day in 8 patients,
and 200mg/day in 3 patients. One patient underwent
pulmonary vein isolation by catheter ablation for
recurrence of paroxysmal AF. The eﬃcacy of
bepridil for converting to sinus rhythm did not diﬀer
between patients with and without underlying
heart disease (73% vs. 67%). Although the rate of
conversion to sinus rhythm was slightly higher in
patients with LAD < 40mm than in patients with
LAD  40mm, the diﬀerence was not signiﬁcant
(78% vs. 63%). Heart rate decreased signiﬁcantly
after bepridil treatment from 71:1 14:2 beats/min
to 58:0 11:2 beats/min (p < 0:05). QT and QTc
intervals during sinus rhythm were signiﬁcantly
prolonged after bepridil treatment from 0:39
0:03 sec to 0:46 0:04 sec (p < 0:01) and from
0:42 0:03 to 0:44 0:03 (p < 0:05), respectively
(Table 1, 2). Although torsade de pointes was not
recognized, marked QT prolongation (0.60 sec) was
observed in 1 patient during the administration of
bepridil of 200mg daily. In this patient, QT interval
was normalized (0.45 sec) after reduction of bepridil
to 150mg daily and AF did not recur.
Discussion
The present study demonstrated a favorable result
with bepridil for treatment of AFL following
administration of class I antiarrhythmic drugs for
paroxysmal AF. Bepridil treatment may be simple
and eﬀective, and seems to be an alternative therapy
for catheter ablation in patients with class IA or
IC antiarrhythmic drug-induced AFL. However,
patients should be monitored to watch for QT
prolongation during the treatment.11)
Table 1 Clinical Characteristics of 17 patients with Class I Atrial Flutter
Case Age(years) Sex UHD
LVEF
(%)
LAD
(mm)
AF duration
(months)
Class I drugs
for AF
Conversion to
SR by bepridil
Meintenace of
SR by bepridil
Dose of bepridil (mg)
Initial/maintenance
1 75 F HT 68 46 3 Pil no no 150/—
2 66 M OMI 51 41 1 Cib yes yes 150/150
3 59 M none 68 38 13 Fle yes no 150/—
4 62 M HT 74 37 108 Cib yes yes 200/150
5 58 M none 72 34 72 Cib,Pro yes yes 100/150
6 69 F HT 64 50 36 Cib yes yes 150/150
7 76 M none 70 40 21 Pil yes yes 100/200
8 57 M MS 72 50 46 Pil yes no 150/—
9 71 M HT 73 37 72 Pil yes no 150/—
10 49 M none 71 38 54 Cib yes yes 200/200
11 57 M HT 64 37 2 Pil yes yes 150/150
12 65 M none 70 28 72 Pil yes yes 150/200
13 68 M HT 67 32 111 Fle yes yes 100/150
14 65 M OMI 49 45 11 Apr yes yes 200/150
15 74 M HT 72 45 144 Pil yes yes 100/100
16 57 M AS 74 44 1 Cib yes yes 150/150
17 69 M none 75 43 1 Pil no no 150/—
UHD: underlying heart disease, LVEF: left ventricular ejection fraction, LAD: left atrial diameter, AF: atrial ﬁbrillation, SR:
sinus rhythm, HT: hypertension, OMI: old myocardial infarction, MS: mitral stenosis, AS: aortic stenosis, Pil: pilsicainide,
Cib: cibenzoline, Fle: ﬂecainide, Pro: propafenone, Apr: aprindine
Table 2 Changes in ECG Parameters after Bepridil Treat-
ment
Control After bepridiltreatment P value
Heart rate
(beats/min)
71:7 14:2 58:0 11:2 p < 0:05
QT interval
(sec)
0:39 0:03 0:46 0:04 p < 0:01
QTc interval 0:42 0:03 0:44 0:03 p < 0:05
Sinus rhythm with class I drug
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Mechanism of termination of class I anti-
arrhythmic drug-induced AFL and maintenance of
sinus rhythm by bepridil
Depression of conduction velocity of atrial tissue
by a class I drug, especially a class IC agent, may
facilitate reentry by slowing and organization of
intraatrial conduction.3,5) This prevents the simulta-
neous occurrence of the multiple reentrant circuits
necessary for perpetuation of AF and results in a
single atrial reentrant circuit manifested as AFL.3)
Class I antiarrhythmic agents also can slow isthmus
conduction and limit transverse conduction across
the crista terminalis, which leads to perpetuation of
isthmus-dependent AFL.4) In addition, the class IA
or IC drugs may induce some serious conditions
in patients with AFL. The obvious danger is the
development of a fast ventricular rate, because the
relative slow atrial rate caused by the class IA or IC
agent with or without an antichorinergic eﬀect may
be followed by 1:1 atrioventricular conduction.5)
This can lead a cardiac catastrophe in patients with
AF. In order to terminate the AFL, prolongation of
the refractory period within the tachycardia circuit is
more important than slowing the conduction veloc-
ity.13) Bepridil has multiple ion-channel blocking
eﬀects: sodium, potassium, and calcium chan-
nels.9,14) Bepridil especially blocks the multiple
components of the potassium currents including
IKr, IKs,
15) IK-ur,
16) IK-Ach,
17) and IK-ATP.
18) The precise
mechanism of eﬃcacy for AFL in the treatment of
bepridil is unknown. These potassium channel
blocking actions may prolong the action potential
duration, which leads to prolongation of the atrial
refractory period, following termination of the AFL
and maintenance of sinus rhythm. Bepridil also has a
T-type calcium channel blocking eﬀect, which can
prevent electrical atrial remodeling for a long time
compared with L-type calcium channel blockers.19)
Recently, bepridil has been reported to suppress the
shortening of atrial eﬀective refractory period in a
canine rapid atrial stimulation model.20) This reverse
electrical remodeling eﬀect may contribute to main-
tenance of sinus rhythm.
Efﬁcacy of medical treatment for class I anti-
arrhythmic drug-induced AFL
Recently, the eﬃcacy of combination therapy with
class I drugs and bepridil has been reported in
patients with class I drug-induced AFL. Suzuki et
al.21) has reported that 15 of the 16 patients (94%)
with class I drug-induced AFL were restored to sinus
rhythm 35 5 days after additional administration
of bepridil while class IC drugs were continued. In
addition, 12 patients (75%) maintained sinus rhythm
during the follow-up period of 21 5 months
without any serious complications. However, the
combination therapy between class IC drugs and
bepridil may increase the possibility of proarrhyth-
mias. Our therapeutic strategy with bepridil after
cessation of the class I agent is simple and is as
eﬀective as the previously reported combination
therapy with class IC and bepridil; 88% of the
patients restored sinus rhythm after an average of 21
days and sinus rhythm was maintained in 80% of the
patients for an average of 23.6 months, and may
lower the possibility of adverse eﬀects. Bepridil has
been reported to be eﬀective for maintenance of
sinus rhythm in patients with paroxysmal and
persistent AF.8,9) Therefore, we propose bepridil as
a ﬁrst-line drug for class I antiarrhythmic drug-
induced AFL. But an additional class I drug may be
necessary in some patients.
Study limitations
First, our study included only a small number of
patients and had no controls. We may have over-
estimated the eﬃcacy of conversion to sinus rhythm
by bepridil. In some patients, especially in patients
with conversion to sinus rhythm within a week, class
I drug-induced AFL may restore sinus rhythm only
by cessation of the class I drug. We could not deny
this possibility because we had no controls. A larger
number of patients and controls are necessary to
verify our results. Second, although sinus rhythm
was maintained in most of the patients, paroxysmal
AF may occur with some patients without any
obvious symptoms. Anti-coagulant therapy with
warfarin must be continued in all of our study
patients even though sinus rhythm is maintained.
Conclusions
Bepridil treatment may be safe and eﬀective for
class I drug-induced AFL in patients with parox-
ysmal AF to restore and maintain sinus rhythm as an
alternative therapy for catheter ablation. However,
we should carefully monitor the QT interval during
the bepridil treatment.
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